Jose Solis-Ruiz

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 6

Top Topics

Squamous Cell Carcinoma

End Stage Renal Disease

Ejection Fraction

Top Venues

Blood cancer journal

This page only lists publications with an associated author ORCID identifier.

Publications

Yonghong Li, Jose Solis-Ruiz, Fei Yang, Nicola Long, Carmen H Tong, Felicitas L Lacbawan, Frederick K Racke, Richard D Press
NGS-defined measurable residual disease (MRD) after initial chemotherapy as a prognostic biomarker for acute myeloid leukemia. Blood cancer journal 13 (1) (2023)
Yonghong Li, Jose Solis-Ruiz, Fei Yang, Nicola Long, Carmen H Tong, Felicitas L Lacbawan, Frederick K Racke, Richard D Press
NGS-defined measurable residual disease (MRD) after initial chemotherapy as a prognostic biomarker for acute myeloid leukemia. Blood cancer journal 13 (1) (2023)
Yonghong Li, Jose Solis-Ruiz, Fei Yang, Nicola Long, Carmen H Tong, Felicitas L Lacbawan, Frederick K Racke, Richard D Press
NGS-defined measurable residual disease (MRD) after initial chemotherapy as a prognostic biomarker for acute myeloid leukemia. Blood cancer journal 13 (1) (2023)
Yonghong Li, Jose Solis-Ruiz, Fei Yang, Nicola Long, Carmen H Tong, Felicitas L Lacbawan, Frederick K Racke, Richard D Press
NGS-defined measurable residual disease (MRD) after initial chemotherapy as a prognostic biomarker for acute myeloid leukemia. Blood cancer journal 13 (1) (2023)
Yonghong Li, Jose Solis-Ruiz, Fei Yang, Nicola Long, Carmen H Tong, Felicitas L Lacbawan, Frederick K Racke, Richard D Press
NGS-defined measurable residual disease (MRD) after initial chemotherapy as a prognostic biomarker for acute myeloid leukemia. Blood cancer journal 13 (1) (2023)
Yonghong Li, Jose Solis-Ruiz, Fei Yang, Nicola Long, Carmen H Tong, Felicitas L Lacbawan, Frederick K Racke, Richard D Press
NGS-defined measurable residual disease (MRD) after initial chemotherapy as a prognostic biomarker for acute myeloid leukemia. Blood cancer journal 13 (1) (2023)